Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provide... [Read more]
Industry Medical DevicesSector HealthcareIPO Date Feb 10, 2011Employees 818Stock Exchange NASDAQTicker Symbol LABWebsite https://www.standardbio.com Full Company Profile Financial PerformanceIn 2024, Standard BioTools's revenue was $174.43 million, an increase of 64.03% compared to the previous year's $106.34 million. Losses were -$184.90 million, 147.7% more than in 2023.
Financial Statements Analyst SummaryAccording to 2 analysts, the erage rating for LAB stock is "Hold." The 12-month stock price target is $1.35, which is a decrease of -8.16% from the latest price.
Price Target $1.35 (-8.16% downside) Analyst Consensus: Hold Stock Forecasts